Home Health & Wellness Testoterone Replacement Therapy May Not Prevent Diabetes Progression in Hypogonadal Men, Reveals New Study

Testoterone Replacement Therapy May Not Prevent Diabetes Progression in Hypogonadal Men, Reveals New Study

Reading Time: 2 minutes

As rates of diabetes and low testosterone continue to rise among middle-aged men, treatments that effectively address both conditions are needed.

But a recent study, published in JAMA Internal Medicine, has cast doubt on the efficacy of testosterone replacement therapy (TRT) as a means to prevent or treat diabetes in men with hypogonadism. This research, part of the larger TRAVERSE randomised clinical trial, specifically examined the effect of TRT on men aged 45 to 80 who were diagnosed with prediabetes or diabetes in addition to hypogonadism.

The study involved a group of men who were either experiencing prediabetes – a stage where blood sugar levels are higher than normal but not yet high enough to be classified as diabetes – or already diagnosed with diabetes. These men also had hypogonadism, a condition characterised by low levels of testosterone. Participants were randomly assigned to receive either testosterone gel or a placebo, allowing for a controlled comparison between the two groups.

Contrary to what might have been expected, the results showed that testosterone therapy did not significantly impact the progression from prediabetes to diabetes. Additionally, in those already diagnosed with diabetes, TRT did not show a notable improvement in glycemic control compared to the placebo group. These findings suggest that TRT, while effective in treating specific symptoms of hypogonadism, may not be beneficial in managing blood sugar levels or preventing the onset of diabetes in this patient population.

Testosterone replacement therapy has been widely used to address various symptoms associated with hypogonadism, including fatigue, low libido, and muscle weakness. However, its role in metabolic processes, particularly in relation to diabetes, has been less clear. This study contributes to a growing body of evidence suggesting that while TRT can improve certain health aspects for men with hypogonadism, its utility in diabetes management is limited.

The findings underscore the importance of a comprehensive approach to diabetes management. For men with hypogonadism, prediabetes or diabetes, relying solely on TRT may not yield the desired results in terms of glycemic control. A more effective strategy would involve a combination of lifestyle changes, dietary adjustments, regular exercise, and medication as prescribed for diabetes management. This holistic approach is crucial to effectively managing the condition and improving overall health outcomes.

Experts in the field suggest that these findings should inform clinical practices and patient consultations. For men with hypogonadism considering TRT, it is essential to have a clear understanding of what the therapy can and cannot do, particularly regarding diabetes risk and management. Future research should continue to explore the relationship between testosterone levels and metabolic diseases, potentially uncovering new therapeutic targets or strategies.

© Copyright 2014–2034 Psychreg Ltd